Campbell David Alan
President and CEO
Campbell David Alan has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 1, 2026.
On the most recent filing, Campbell David Alan is listed as President and CEO at Janux Therapeutics, Inc. Inside the rolling window, Campbell David Alan reported no open-market purchases and 1 open-market sale totaling $111K in JANX.
Companies traded
Other insiders at JANX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$111K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Campbell David Alan made?
Campbell David Alan has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Campbell David Alan trade?
Campbell David Alan has filed SEC Form 4 disclosures for 1 company, including JANX.
When was Campbell David Alan's most recent SEC Form 4 filing?
Campbell David Alan's most recent SEC Form 4 filing on Tracefour is dated Aug 1, 2026.
What is Campbell David Alan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Campbell David Alan is listed as President and CEO.
What is Campbell David Alan's total buy and sell value in the current window?
Inside the rolling retention window, Campbell David Alan bought $0 and sold $111K based on SEC Form 4 filings.
What was Campbell David Alan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,072 JANX shares on 2026-01-02, worth $111K, per SEC Form 4 filings.